Barclays Maintains Equal-Weight on CRISPR Therapeutics, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Equal-Weight rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $56 to $61.
December 11, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has maintained an Equal-Weight rating on CRISPR Therapeutics and raised the price target to $61, indicating a positive outlook on the stock.
The increase in price target by Barclays reflects a positive sentiment towards CRISPR Therapeutics' stock. While the rating remains unchanged, the higher price target suggests that Barclays sees potential for the stock to grow in value in the short term. This could lead to increased investor confidence and a potential uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100